Skip to main content
Log in

Treatment of acute myeloid leukemia and blastic phase of chronic myeloid leukemia with combined eflornithine (alpha difluoromethylornithine) and methylglyoxal-bis-guanyl hydrazone (methyl-GAG)

  • Short Communication
  • Eflornithine-MGBG, Myeloid Leukemia
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

A combined eflornithine-MGBG treatment was studied in patients with acute myeloid leukemia (AML) or blastic transformation of chronic myeloid leukemia (BT CML). The first ten patients (5 AML, 5 BT CML) received i.v. or p.o. eflornithine 6 g m-2 day-1 and i.v. MGBG 500 mg/m2 once a week. The duration of treatment was 5–37 days (median 15) with one to five MGBG infusions (median 2). The results were complete response (CR) in one patient, partial response (PR) in four, minimal response (MR) in one and failure (F) in four. Pronounced side effects, including severe mucositis, gastrointestinal disturbances and skin infiltration, were observed in eight patients. As the four PRs were achieved in patients with BT CML, it was decided also to study ten patients with this indication. In attempts to decrease the incidence and severity of unwanted effects, lower doses of eflornithine-MGBG were used, i.e., eflornithine 4 g m-2 day-1 and MGBG 200 mg m-2 once a week. The duration of treatment was 9–110 days (median 46), with 2–14 MGBG infusions (median 6). Responses observed were CR in two patients (in one of whom it was only transient), transient PR in two, transient MR in four, and F in two. Treatment at lower doses was better tolerated, thus allowing a longer duration of treatment. Five of ten patients had moderate or severe gastrointestinal disturbances and one patient had a severe subjective hearing loss. The eflornithine-MGBG combination may prove to be a useful alternative treatment for AML and BT CML, but comparative trials will ultimately be necessary for a more definitive assessment of the combination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Alhonen-Hongisto L, Seppänen P, Jänne J (1980) Intracellular putrescine and spermidine deprivation induces uptake of the natural polyamines and methylglyoxal bis (guanylhydrazone). Biochem J 192: 941–945

    Google Scholar 

  2. Baccarini M, Corbelli G, Tura S and the Italian Cooperative Study Group on chronic myeloid leukemia (1981) Early splenectomy and polychemotherapy versus polychemotherapy alone in chronic myeloid leukemia. Leuk Res 5: 149–157

    Google Scholar 

  3. Bernard J (1967) Acute leukemia treatment Cancer Res 27: 2565–2569

    Google Scholar 

  4. Boiron M, Jacquillat C, Weil M, Bernard J (1965) Combination of methylglyoxal bis (guanylhydrazone) (NSC-32946) and 6-mercaptopurine (NSC-755) in acute granulocytic leukemia. Cancer Chemother Rep 45: 69–73

    Google Scholar 

  5. Cunningham I, Gee T, Dowling M, Chaganti R, Bailey R, Hopfan S, Bowden L, Turnbull A, Knapper W, Clarkson B (1979) Results of treatment of Phl + chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol). Blood 53: 375–395

    Google Scholar 

  6. Freireich EJ, Frei E III, Karon M (1962) Methylglyoxal bis (guanylhydrazone): a new agent active against acute myelocytic leukemia. Cancer Chemother Rep 16: 183–186

    Google Scholar 

  7. Gastaut JA, Mascret B, Maraninchi D, Tubiana-Mathieu N, Carcassonne Y (1983) Treatment of acute leukemia with combined alpha-difluoromethyl-ornithine (alpha DFMO) and methyl-GAG in adult patients. Second European Conference on Clinical Oncology, Amsterdam 2–5 November

  8. Goldman JM, Baughan A (1983) Application of bone marrow transplantation in chronic granulocytic leukemia. Clin Haematol 12: 739–753

    Google Scholar 

  9. Herman TS, Durie BG, Hutter JJ Jr (1982) Treatment of patients with refractory myelogenous leukemia with BCOMM (1,3-bis-chloro) (2-chloroethyl)-1-nitrosourea (BCNU), Oncovin (vincristine), cyclophosphamide, high-dose methotrexate and methylglyoxal-bis-guanylhydrazone (MGBG). Cancer Chemother Pharmacol 8: 73–75

    Google Scholar 

  10. Jänne J, Alhonen-Hongisto L, Seppänen P, Simes M (1981) Use of polyamine antimetabolites in experimental tumors and in human leukemia. Med Biol 59: 448–457

    Google Scholar 

  11. Knight WA III, Fabian C, Costanzi JJ, Jones JJ, Coltman CA Jr (1983) Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in lymphoma and Hodgkin's disease. A phase II trial of the Southwest Oncology Group. Invest New Drugs 1: 235–237

    Google Scholar 

  12. Kuhn JG, Knight WA III, McDaniel TM, Coltman CA Jr, Whitecar JP, Fabian C, Costanzi JJ (1982) Methylglyoxal-bis (guanylhydrazone) (methyl-GAG) in the management of non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 1: 163

    Google Scholar 

  13. Letendre L, Kiely JM, Hoagland HC (1984) Reinduction chemotherapy for acute non lymphocytic leukemia. Mayo Clin Proc 59: 618–621

    Google Scholar 

  14. Levi JA, Wiernik PH (1975) Combination therapy with 5-azacytidine (NSC-102816) and methyl-GAG (NSC-32946) in previously treated adults with acute non-lymphocytic leukemia. Cancer Chemother Rep 59: 1043–1045

    Google Scholar 

  15. Levin RH Brittain GM, Freireich EJ (1963) Different patterns of remission in acute myelocytic leukemia: a comparison of the effects of methylglyoxal-bis-(guanylhydrazone) and 6-mercaptopurine. Blood 21: 689–698

    Google Scholar 

  16. Levin RH, Henderson E, Karon M, Freireich EJ (1964) Treatment of acute leukemia with methylglyoxal bis (guanylhydrazone) (methyl-GAG). Clin Pharmacol Ther 6: 31–42

    Google Scholar 

  17. Metcalf R, Bey P, Danzin C (1978) Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E. C. 4.1.1.17) by substrate and product analogues. J Am Chem Soc 100: 2551–2553

    Google Scholar 

  18. Schwarzenberg L, Schneider M, Cattant A, Amiel JL, Schlumberger JR, Mathé G (1966) Le traitement des leucémies aiguës par la methylglyoxal-bis (guanyl-hydrazone) et son association avec la 2-hydroxystilbamidine. Sem Hop Paris 42: 2955–2957

    Google Scholar 

  19. Seppänen P, Alhonen-Hongisto L, Jänne J (1981) Polyamine deprivation-induced enhanced uptake of methylglyoxal-bis-(guanylhydrazone) by tumor cells. Biochim Biophys Acta 674: 169–177

    Google Scholar 

  20. Simes M, Seppänen P, Alhonen-Hongisto L, Jänne J (1982) Synergistic action of two polyamine antimetabolites leads to a rapid therapeutic response in childhood leukemia. Int J Cancer 28: 567–570

    Google Scholar 

  21. Sjoerdsma A, Schechter PJ (1984) Chemotherapeutic implications of polyamine biosynthesis inhibition. Clin Pharmacol Ther 35: 287–300

    Google Scholar 

  22. Spiers AS (1979) Metamorphosis of chronic granulocytic leukemia: diagnosis, classification and management. Br J Haematol 41: 1–7

    Google Scholar 

  23. Splinter TAW, Romijn JC (1986) Phase I study of alpha-difluoromethylornithine and methyl-GAG. Eur J Cancer Clin Oncol 22: 61–67

    Google Scholar 

  24. Warrell RP Jr, Burchenal JH (1983) Methylglyoxal-bis (guanylhydrazone) (methyl-GAG): current status and future prospects. J Clin Oncol 1: 52–65

    Google Scholar 

  25. Warrell RP Jr, Straus DJ, Young CW (1982) Combination chemotherapy of patients with relapsed malignant lymphoma using methyl-GAG and teniposide (VM-26). Cancer Treat Rep 66: 1121–1125

    Google Scholar 

  26. Warrell RP Jr, Coonley CJ, Burchenal JH (1983) Sequential inhibition of polyamine synthesis. A phase I trial of DFMO (alpha-difluoromethylornithine) and methyl-GAG (methylglyoxal-bis [guanylhydrazone]) Cancer Chemother Pharmacol 11: 134–136

    Google Scholar 

  27. Wiernik PH (1984) The current status of therapy and prevention of blast crisis of chronic myelocytic leukemia. J Clin Oncol 2: 329–335

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gastaut, JA., Tell, G., Schechter, P.J. et al. Treatment of acute myeloid leukemia and blastic phase of chronic myeloid leukemia with combined eflornithine (alpha difluoromethylornithine) and methylglyoxal-bis-guanyl hydrazone (methyl-GAG). Cancer Chemother. Pharmacol. 20, 344–348 (1987). https://doi.org/10.1007/BF00262590

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00262590

Keywords

Navigation